EL7.AI
StocksMedium•19 November 2026•
1 min read

Biohaven Stock Surges 8% Following Positive Early Cancer Trial Data

Key Facts

1Biohaven Ltd. shares rose more than 8% following the release of new early clinical oncology data.
2The stock's climb occurred despite a 1.8% decline in the healthcare sector and a 0.23% drop in the S&P 500.

Biohaven Ltd. shares rose more than 8% following the release of new early clinical oncology data. Benzinga reported that the surge was driven by positive investor reaction to the company's cancer treatment pipeline results.

The stock's climb occurred despite a 1.8% decline in the healthcare sector and a 0.23% drop in the S&P 500 index. BHVN closed at $12.9 on November 18, 2026, before experiencing the upward momentum during the November 19, 2026 session.

Open on chart